All articles tagged with #revolution medicines
Merck ended discussions to acquire Revolution Medicines due to a valuation disagreement, effectively halting the deal. Investor interest in Revolution’s cancer-drug pipeline remains buoyant ahead of several key clinical trial results later this year, with Mizuho Securities estimating Revolution’s pancreatic cancer drug could reach about $10 billion in annual global sales by 2035 if the trials prove successful and safe.
Merck is in negotiations to acquire biotech firm Revolution Medicines, with the deal not yet finalized and other bidders potentially involved, causing Revolution's shares to rise.
Merck is in negotiations to acquire Revolution Medicines, a cancer drug developer, for up to $32 billion, signaling a significant move in the biotech and pharmaceutical industry.
EQRx, a biotech company, will be acquired by Revolution Medicines in an all-stock transaction. As part of the merger, EQRx's ongoing R&D portfolio programs will be discontinued, and the intellectual property will be returned to its partners. The deal will provide Revolution Medicines with $1 billion in net cash, which will be used to focus on RAS inhibitor candidates and mutant-selective RAS(ON) programs. The new capital will help fund pivotal clinical trials for Revolution Medicines' lead candidate, RMC-6236, potentially starting in 2024.